Sélectionner une page

/Encoding /WinAnsiEncoding Cliquez sur un pictogramme pour aller directement à la rubrique le concernant. One month post-vaccination ≥ 98.5% of study participants achieved seroprotective antibody levels (≥ 0.1 IU/ml) for diphtheria and tetanus, and ≥ 84% achieved booster responses to the pertussis antigens. The benefits versus the risks of administering REPEVAX during pregnancy should be evaluated. q7�E���]��?���\]���뿝}�>����߹X)S5-f�"�L��H"��GWJF�=�#��W�,|�W�])����.�g���V/X��� �mm�n�Ubo���V_e���Q�s�s�?��w�ǯB?�������4T��}I��-Xf�[�����v�������T�졾�w/����T'���2��J&3n�h���Bh2"���g��G���!Ic�e,!�H���8�X�)5�i.��� �Y,�ݰi����x) �ax%�QŢ��w��A��Յ(G�'��q&��E$�ąU'�>�&:��Fw�!V�2��y|%c��K���1���Tۧ�g� �:�e�€��+�$��ƛ�Td����3���I�Yo�5�v��>�/��^��nG�k�u�j7\�+x�,��T� ��` �� �v�� ��] �e�R?��`�6(�z�(}c�wm�n�o�G���5�� Iw�o�/������ %���� /FontDescriptor 84 0 R /Leading 42 The clinical relevance of this observation is unknown. /Widths [250 0 0 0 0 0 0 0 0 0 Reporting suspected adverse reactions after authorisation of the medicinal product is important. /MaxWidth 2665 As with other inactivated vaccines, it is not expected that vaccination with REPEVAX during any trimester would harm the fetus. Extensive limb swelling which may extend from the injection site beyond one or both joints and is frequently associated with erythema, and sometimes with blisters has been reported following administration of REPEVAX. << /Type /FontDescriptor 500 500 333 389 278 500 500 722 500 500 /AvgWidth 441 Based on the serology follow-up and repeat vaccination data, REPEVAX can be used instead of a dT vaccine or dT-IPV vaccine to boost immunity to pertussis in addition diphtheria, tetanus and polio. The benefits versus the risk of administering REPEVAX to breastfeeding women should be evaluated by the health-care providers. They all resolved without sequelae. Therefore, the frequency category “Not known” is assigned to these adverse events. Passive protection of neonates and infants against pertussis. Active immunization against diphtheria, tetanus, pertussis and poliomyelitis in persons from 3 years of age as a booster following primary immunization. ���ȪLf'_ƲJ9�����?��Y �Ȱ#�_}o�4��-�����X�A݁D�/�0�j}~�v+^��]}�^�j}?��O��I-��T�V��w5���i�Cˮj�I���ڎr{���rs�V}QMM(��%�X~,6�*��6$w���C~�d�CB�j��1�O��E��!���*RY�,�!��U*}'� Table 3: Persistence of Seroprotection/Seropositivity Rates in Children, Adolescents and Adults at 3-, 5- and 10- years following a dose of ADACEL (Tdap component of REPEVAX) (PPI Population1), N = number of subjects with available data; SN: seroneutralisation; ELISA: Enzyme Linked Immunoassay. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 556 444 556 444 The normal appearance of the vaccine is a uniform cloudy, white suspension which may sediment during storage. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. repevax suspension for injection in a pre-filled syringe. The clinical relevance of this observation is unknown. REPEVAX should not be used for primary immunization. endstream 0 0 250 333 250 278 500 500 500 500 667 556 611 722 722 944 722 722 611 0 Interaction studies have not been carried out with other vaccines, biological products or therapeutic medications. Dans des essais cliniques conduits dans une population pour laquelle le vaccin est indiqué (voir rubrique Indications thérapeutiques), l'efficacité du vaccin était de 50 à 70 % (par exemple chez les sujets atteints de diabète sucré, d'affection cardiaque ou pulmonaire chronique et d'asplénie). /Type /FontDescriptor Zona : Pour les personnes entre 65 et 74 ans. In these situations and following official recommendations the administration of REPEVAX by deep subcutaneous injection may be considered, although there is a risk of increased local reactions. << /GS7 89 0 R 0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer) with attached needle and needle guard (translucent polypropylene rigid safeshield and polyisoprene) - pack size of 1, 10 or 20. REPEVAX can be used in the management of tetanus prone injuries with or without concomitant administration of Tetanus Immunoglobulin according to official recommendations. endobj /XHeight 250 722 556 667 0 722 1000 722 722 0 0 Persistence of seroprotection to diphtheria and tetanus, and seropositivity to pertussis is summarised in Table 3. Procedures should be in place to prevent falling injury and manage syncopal reactions. << << Contre-indications REPEVAX préviendra uniquement ces maladies si elles sont causées par les bactéries ou virus ciblés par le vaccin. Quatre semaines après la vaccination, la réponse immunitaire VZV spécifique observée suite à  une administration concomitante n'était pas similaire à la réponse immunitaire VZV spécifique observée suite à une administration non concomitante. /LastChar 121 /Type /Font /Ascent 891 2Age at which subjects received a dose of ADACEL, 3Percentage of subjects with antibodies ≥ 4 EU/mL for PT, FHA and PRN, and ≥ 17 EU/mL for FIM for the 3 year follow-up; ≥ 4 EU/mL for PT, FIM and PRN, and ≥ 3 EU/mL for FHA for the 5-year and 10-year follow-up. 0 444] /E 6929 Possible side effects 5. active substance(s): diphtheria toxoid adsorbed purified / pertactin adsorbed purified / pertussis adsorbed purified filamentous haemagglutinin / pertussis fimbrial agglutinogens 2 and 3 adsorded purified / pertussis toxoid purified adsorbed / poliomyelitis inactivated virus type pdf options: view fullscreen download pdf REPEVAX should be used in accordance with official recommendations. The number and schedule of doses should be determined according to local recommendations. >> Table 2: Immune responses 4 weeks after vaccinationAntigen, † Primed with DTaP at 3 and 5 months with a booster at 12 months of age, ‡ Primed with DTwP at 2, 3 and 4 months of age. Important, Résumé des Caractéristiques Produits (RCP) des autorisations de mise sur le marché (AMM) françaises et européennes, Livret des interactions médicamenteuses de l’Agence nationale de sécurité du médicament et des produits de santé (ANSM), Documents de référence de la Haute Autorité de Santé (HAS) : fiches de transparence, fiches de bon usage, documents SAM (Système d’Aide à la décision par Médicament), Prix et remboursements du Comité économique des produits de santé (CEPS), Informations des laboratoires titulaires de l’AMM (CF supra dans l’onglet « Autres informations » de cette page), Assurance maladie (CNAMTS) : guide des affectations de longues durées (ALD), Agence technique de l'information sur l'hospitalisation (ATIH) : classification CIM10, Organisation mondiale de la santé (OMS) : classification ATC, Pharmacopée européenne : Standard Terms et classification EPhMRA, Ministère de la santé : substances dopantes. diphtheria, tetanus, polio, pneumococcal, meningococcal) in infants born to women vaccinated with REPEVAX during pregnancy. 0 0 0 0 400 0 0 0 0 0 Documents de presse. « REPEVAX est indiqué pour l'immunisation active contre la diphtérie, le tétanos, la coqueluche et la poliomyélite chez les sujets à partir de l'âge de 3 ans en rappel après primovaccination. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. /Type /Catalog /Name /F1 << >> endobj * As lower confidence limit (p = 0.95) of activity measured according to the assay described in the European Pharmacopoeia. We comply with the HONcode standard for trustworthy health information -, REPEVAX SUSPENSION FOR INJECTION IN A PRE-FILLED SYRINGE, Diphtheria, Tetanus, Pertussis (Acellular, Component) And Poliomyelitis (Inactivated) Vaccine (Adsorbed). SYR(with chlorobr. The immunogenicity of the vaccine could be reduced by immunosuppressive treatment or immunodeficiency. 82 0 obj Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more. This site uses cookies. - to any residual substances carried over from manufacture (formaldehyde, glutaraldehyde, streptomycin, neomycin, polymyxin B and bovine serum albumin), which may be present in undetectable trace amounts. Immunogenicity following repeat vaccination. The preferred site is into the deltoid muscle. /CapHeight 693 0 0 0 0 0 0 0 0 0 0 Limited clinical data have shown there is interference with the immune response to other antigens (i.e. Shake the prefilled syringe well to uniformly distribute the suspension before administering the vaccine. /Tabs /S Regarding the interval between a booster dose of REPEVAX and preceding booster doses of diphtheria and/or tetanus containing vaccines, the official recommendations should generally be followed. The safety profile of REPEVAX in 390 children 3 to 6 years of age as presented in Table 1 is derived from two clinical studies: - In a clinical study, 240 children were primed at 3, 5 and 12 months of age with a DTaP vaccine with no additional dose in the second year of life. /FirstChar 32 Mon enfant veut des vêtements et accessoires de marque. >> REPEVAX can be used for repeat vaccination to boost immunity to diphtheria, tetanus and pertussis at 5 to 10 year intervals (see section 5.1). /Root 80 0 R Diphtheria, Tetanus, Pertussis (Acellular, Component) And Poliomyelitis (Inactivated) Vaccine (Adsorbed) is reported as an ingredient of Repevax in the following countries: Important Notice: The Drugs.com international database is in BETA release. /Filter /FlateDecode /Info 41 0 R Toutefois dans une étude de cohorte d'efficacité en vie réelle menée aux Etats-Unis chez 35 025 adultes de 60 ans et plus, aucune augmentation du risque de zona n'a été observée chez les sujets vaccinés en même temps par ZOSTAVAX et le vaccin pneumococcique polyosidique 23-valent (n=16 532) comparativement aux sujets vaccinés par ZOSTAVAX un mois à un an après le vaccin pneumococcique polyosidique 23-valent (n=18 493) en pratique courante. /LastChar 32 In persons who have a history of serious or severe reaction within 48 hours of a previous injection with a vaccine containing similar components, administration of REPEVAX vaccine must be carefully considered. Transient severe swelling of the injected upper arm was reported in <1% of children aged 5 to 6 years. What you need to know before REPEVAX is given to you or your child 3. Table 1: Adverse events from clinical trials and worldwide post marketing experience, Anaphylactic reactions, such as urticaria, face oedema and dyspnea*, Convulsions, Vasovagal Syncope, Guillain Barré syndrome, Facial Palsy, Myelitis, Brachial Neuritis, Transient paresthesia/hypoesthesia of vaccinated limb, Dizziness*, Musculoskeletal and connective tissue disorders, General disorders and administration site conditions, Injection site pain, Injection site swelling, Injection site erythema, Irritability, Injection site dermatitis, Injection site bruising, Injection site pruritus, Malaise§, Pallor*, Extensive limb swelling‡, Injection site induration*, † Fever was measured as temperature ≥37.5°C in Children groups and measured as temperature ≥38°C in Adolescents and Adults group, § was observed at a frequency of very common in adolescents and adults, in studies with ADACEL (Tdap component of REPEVAX; containing the same amounts of diphtheria, tetanus and pertussis antigens), Description of selected adverse reactions. La protection d'un vaccin 6-valent vis-à-vis des pneumonies à pneumocoques, critère principal dans ces études, était de 76,1 %, celle d'une préparation 12-valent. Les rappels de l’adulte sont désormais recommandés aux âges fixes de 25 ans, 45 ans et 65 ans, puis à 75 ans, 85 ans, etc. /FontDescriptor 88 0 R The highest frequency from either study is presented. For the full list of excipients, see section 6.1. The immune responses of adults, adolescents and children 3 to 6 years of age one-month after vaccination with REPEVAX are shown in the table below. In clinical trials REPEVAX was given to a total of 1,384 persons including 390 children 3 through 6 years of age and 994 adolescent and adults. /Type /XRef stream 91 0 obj It is recommended to postpone the vaccination until the end of such disease or treatment if practical. REPEVAX appears as a uniform, cloudy, white suspension. These signs and symptoms usually were mild in intensity and occurred within 48 hours following vaccination (Adverse Events have been observed within 24 hours and 7 days following vaccination in children 3 through 6 years). endobj No studies on the effects on the ability to drive or use machines have been performed. 722 333 0 722 611 889 722 722 556 0 Confinement : quels sont ses effets sur l’évolution de l’épidémie ? A persistent nodule at the site of injection may occur with all adsorbed vaccines, particularly if administered into the superficial layers of the subcutaneous tissue. 5 0 obj Conditions de prescription et de délivrance : Adjuvants are added to some vaccines to: help to boost our immune response; make the vaccine more effective and long-lasting; reduce the amount of antigen needed in a vaccine /H [6929 189] /FontBBox [-568 -216 2046 693] /FontName /ArialMT endobj REPEVAX may be administered to pregnant women during the second or third trimester to provide passive protection of infants against pertussis (see sections 4.1, 4.4, 4.6 and 5.1). /F3 87 0 R /Lang (en-US) Une étude a montré que la vaccination est significativement protectrice contre la maladie pneumococcique invasive due à des sérotypes particuliers (exemple: 1, 3, 4, 8, 9V et 14). What REPEVAX is and what it is used for 2. /StemV 42 /BaseFont /TimesNewRomanPS-BoldMT L'efficacité du vaccin polyosidique Pneumococcique multivalent a été établie pour les pneumonies et bactériémies à pneumocoques lors d'essais randomisés contrôlés réalisés sur des mineurs travaillant dans des mines d'or, en Afrique du Sud. The stoppers, plunger stoppers and caps for all presentations of REPEVAX are latex-free. %�쏢 Médicament non soumis à prescription médicale. REPEVAX ne contient aucune bactérie ou virus vivant et il ne peut causer aucune des maladies infectieuses contre lesquelles il protège. /Name /F3 /Leading 33 Healthcare professionals are asked to report any suspected adverse reactions via the Medicines and Healthcare products Regulatory Agency (MHRA), Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. A single injection of one dose (0.5 mL) of REPEVAX should be administered intramuscularly. Syncope (fainting) can occur following, or even before, administration of injectable vaccines, including REPEVAX. 0 0 0 0 0 0 0 0 0 0 85 0 obj Rappelez-vous qu'aucun vaccin ne peut fournir une protection complète à vie chez toutes les personnes qui sont vaccinées. Safety data from 4 randomized controlled trials (310 pregnancy outcomes), 2 prospective observational studies (2670 pregnancy outcomes), 4 retrospective observational studies (81,701 pregnancy outcomes), and from passive surveillance of women who received REPEVAX or ADACEL (Tdap component of REPEVAX; containing the same amounts of diphtheria, tetanus and pertussis antigens) during the 2nd or 3rd trimester have shown no vaccine-related adverse effect on pregnancy or on the health of the fetus/newborn child. /T 109242 Nombre de décès de Covid-19 chez les moins de 65 ans : un indicateur plus fiable pour évaluer les taux d’infection dans les populations; Virus de la fièvre de la Vallée du Rift : mise en évidence d’un mécanisme de l’infection; Espace presse. /Parent 42 0 R 26482.01.11 /Descent -210 This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. /Flags 32 /MediaBox [0 0 612 792] It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. /CapHeight 677 /FontWeight 700 1Eligible subjects for whom immunogenicity data was available for at least one antigen at the specified time-point. Les données n'indiquent pas que l'administration concomitante des deux vaccins altère l'efficacité en vie réelle de ZOSTAVAX. Tout dépend de votre âge : les rappels sont désormais recommandés à 25 ans, 45 ans, 65 ans, puis tous le 10 ans à partir de 65 ans. As with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of the vaccine. Select one or more newsletters to continue. Continue typing to refine. Les résultats d'une étude épidémiologique suggèrent que la vaccination peut assurer une protection pendant au moins 9 ans après l'administration de la dose initiale de vaccin. >> Dans une étude clinique contrôlée en double aveugle, 473 adultes âgés de 60 ans ou plus ont été randomisés pour recevoir une dose de ZOSTAVAX administrée de façon concomitante (n=237), ou non concomitante (n=236) avec le vaccin Pneumococcique polyosidique comportant 23 valences. 0 0 0 0 0 444 500 444 500 444 /PageMode /UseOutlines ]Y/�4����E�%&t���,�Ì���).�"�\ REPEVAX has not been evaluated in fertility studies. Evaluation of pharmacokinetic properties is not required for vaccines. /FontBBox [-558 -216 2000 677] Code Identifiant de Spécialité (CIS) : 60614280, Service médical rendu (SMR) : In the absence of compatibility studies, REPEVAX must not be mixed with other medicinal products. /Flags 32 • 82.4% and 92.7% were seroprotected against diphtheria at a threshold ≥0.1 and ≥0.01 IU/mL, respectively. /Descent -216 In the event of either being observed, discard the medicinal product. endobj >> Discard the vaccine if it has been frozen. , Sc, Classe pharmacothérapeutique : Pneumococcus, antigènes polysaccharidiques purifiés. 78 0 obj Table 1 presents adverse reactions observed in clinical trials and also includes additional adverse events which have been spontaneously reported during the post-marketing use of REPEVAX worldwide. 86 0 obj /Names 65 0 R • Maternal antibody directed against pertussis antigens persists for 2 to 4 months after birth and may be associated with blunting of the infant immune response to active immunization against pertussis (see section 4.4). Cette spécialité est un complément de gamme qui n'apporte pas d'amélioration du service médical rendu. /ItalicAngle 0 Intramuscular injections should be given with care in patients on anticoagulant therapy or suffering from coagulation disorders because of the risk of haemorrhage. Data sources include IBM Watson Micromedex (updated 2 Nov 2020), Cerner Multum™ (updated 2 Nov 2020), ASHP (updated 23 Oct 2020) and others. Distanciation physique : comment la respecter et est-elle efficace contre le Covid-19 ? >> x��K{ܶ�_���O� ��[ںi�T[����ZRZ�2�w�O�� f��ٕ������ �~��g�����E$r�����c{��g������E�JV���=S��H(��D&�H�,Kq����O� Les rapports de la moyenne géométrique des titres en anticorps par sérotype mesurés à 30 jours entre les sujets revaccinés et ceux recevant primovaccination étaient compris entre 0,60 et 0,94 pour les 65 ans et plus et entre 0,62 et 0,97 pour le groupe des 50-64 ans. << À 25 ans, le rappel concerne également la coqueluche. Vaccin diphtérique, tétanique, coquelucheux (acellulaire, multicomposé) et poliomyélitique (inactivé), (adsorbé, à teneur réduite en antigène (s)) - Notice patient: ... Chez les enfants âgés de 3 à 6 ans. ��G�J�|�h�����-(ۍ���/. /FontBBox [-665 -210 2000 728] 87 0 obj endobj Clinical data in adults have demonstrated that there was no clinically relevant difference in rates of adverse reactions associated with administration of REPEVAX as early as 4 weeks, compared to at least 5 years after a preceding dose of tetanus and diphtheria-containing vaccine. x�cd`�g`d`�$��@�5 ��$XL��`��ρ�C ��$x�@�v�HH2 �ND If Guillain-Barré syndrome occurred within 6 weeks of receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid, including REPEVAX should be based on careful consideration of the potential benefits and possible risks. 500 500 500 500 500 500 278 0 0 0 /F1 83 0 R - One hundred and fifty children primed at 2, 3, and 4 months of age with a DTwP vaccine (with no additional dose in the second year of life) received REPEVAX at 3 to 5 years of age. /Prev 109242 Im �V�tћbo�€c;E����7. n���:�W�����6�4��2�Z�����j� ر�M��p� ��ț�m ��P��Jx+���=]�1�&(��1*�h�D@A�t�s�;� ����խ��B��A�.���_�K]�,5VBP��I��W�u��>L �ǫW+&O��?+�1B�~�����9����i�. 333 500 556 278 333 556 278 833 556 500 /ExtGState << In adolescents and adults with an unknown or incomplete diphtheria or tetanus vaccination status against diphtheria or tetanus, one dose of REPEVAX® can be administered as part of a vaccination series to protect against pertussis and poliomyelitis and in most cases also against tetanus and diphtheria. Un rattrapage vaccinal est recommandé jusqu’à l’âge de 24 ans. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. << 0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer), without attached needle, with a tip-cap (chlorobromobutyl elastomer or synthetic isoprene-bromobutyl elastomer) - pack size of 1, 10 or 20. (A pertussis booster response was defined as a post-vaccination antibody concentration ≥ 4 times the LLOQ if the pre-vaccination level was < LLOQ; ≥ 4 times the pre-vaccination level if that was ≥ LLOQ but < 4 times LLOQ; or ≥ 2 times the pre-vaccination level if that was ≥ 4 times the LLOQ). 0 0 0 0 0 0 0 0 0 0 /Size 93 The effect of administration of REPEVAX during lactation has not been assessed. /N 7 /Length 3541 Ce vaccin est utilisé en rappel de la protection contre la diphtérie, le tétanos, la coqueluche et la poliomyélite chez les enfants à partir de l'âge de trois ans, chez les adolescents et les adultes à la suite d'une primovaccination complète. Les jeux vidéo seraient bénéfiques pour votre santé mentale, PNEUMOVAX Injectable boîte de 1 flacon de ½ mL, Rhume : trop de prescriptions médicamenteuses inutiles voire dangereuses, Dépakine : elle multiplie par 5 le risque de troubles du développement, selon une étude, Médicaments sans ordonnance : les dangers de l’automédication pointés du doigt par 60 millions de consommateurs, Maladie de Parkinson : une association alerte sur la pénurie de médicaments, Charte de données personnelles et cookies, Sensation de chaleur au point d'injection, Diminution de la mobilité du membre vacciné, Réaction anaphylactique après administration du vaccin, Forme pharmaceutique : Solution injectable, Voie d'administration : /LastChar 233 A single injection of one (0.5 mL) dose is recommended in all indicated age groups. To view the changes to a medicine you must sign up and log in. To email a medicine you must sign up and log in. /Metadata 64 0 R Grippe saisonnière : Vaccination chaque année pour toutes les personnes âgées de 65 ans et plus. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Most commonly reported reactions following vaccination included local reactions at the injection site (pain, redness and swelling). /Subtype /TrueType REPEVAX (dTcaP) est un vaccin. The differences observed were < 10% and in the majority of subjects, the adverse events were reported as mild to moderate in intensity. 778 389 0 0 667 944 0 778 611 0 /Pages 42 0 R Il est également possible de proposer la vaccination aux personnes âgées de 75 à 79 ans jusqu’en février 2017. The use of REPEVAX in children aged 3 to 5 years is based upon studies in which REPEVAX was given as the fourth dose (first booster) of diphtheria, tetanus, pertussis and poliomyelitis vaccines. Continue, 2. >> startxref Repevax may be available in the countries listed below. >> However, in most of the cases, the antibody concentrations remain above the thresholds established as protective. /Widths [250 0 408 0 0 0 0 180 333 333 /Subtype /TrueType REPEVAX can be used in the management of tetanus prone injuries with or without concomitant administration of Tetanus Immunoglobulin according to official recommendations. FAS: Full Analysis Set – includes all subjects who received the study vaccine dose and for whom the post-vaccination immunogenicity evaluation was available. 1. << /FontName /TimesNewRomanPS-BoldMT The risk appears to be dependent on the number of prior doses of d/DTaP vaccine, with a greater risk following the 4th and 5th doses. REPEVAX, suspension injectable en seringue préremplie. How and when REPEVAX is given 4. Les libellés affichés ci-dessous ne sont que des résumés ou extraits issus des avis rendus par la Commission de la Transparence. /MaxWidth 2614 /Type /Font REPEVAX should not be administered into the gluteal area; intradermal or subcutaneous routes should not be used (in exceptional cases the subcutaneous route may be considered, see section 4.4). Le vaccin n'est pas efficace dans la prévention de l'otite moyenne aigüe, de la sinusite et des autres infections courantes des voies aériennes supérieures. /Ascent 891 %%EOF /L 109731 Si vous n’avez pas été vacciné contre la méningite à méningocoque C, il est fortement recommandé de le faire. (See Table 1). Classe pharmacothérapeutique : Vaccin contre la diphtérie, le tétanos, la coqueluche et la poliomyélite - code ATC : J07CA02. 84 0 obj 410, Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. endobj Les rappels de l'adulte sont recommandés à âges fixes (25, 45, 65 ans puis tous les 10 ans).

Priorix Effets Secondaires, Photos Ventre Grossesse Mois Par Mois, Météo Argentine Décembre, Comment Saisir La Cour Européenne Des Droits De L'homme, Actrice 10 Pour Cent, Sidiki Diabaté Biographie, La Belle Et La Bête Questions De Compréhension 6ème, Accident D'avion En Direct, Géante Du Jersey, Château à Vendre 1 Euro Symbolique 2019, Décembre En Anglais, Mef Lycée Exemple,